Phase 3B study evaluating superiority of daily dosing vs approved on/off oral edaravone dosing over 48 weeks in patients with amyotrophic lateral sclerosis (MT-1186-A02)

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2023-12, Vol.455, p.121719, Article 121719
Main Authors: Salah, Alejandro, Desilva, Shari, Zinman, Lorne, Chum, Marvin, Chio, Adriano, Ludolph, Albert C., Sobue, Gen, Doyu, Manabu, Selness, Daniel, Todorovic, Vesna, Hirai, Manabu, Wamil, Art, Apple, Stephen
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0022-510X
DOI:10.1016/j.jns.2023.121719